Taisho have entered in to an agreement with Chugai to co-market ED-71, an activated vitamin D derivative that Chugai is currently developing in Japan for the treatment of osteoporosis
Filed under: Nuclear Receptor | Tagged: agonist, Chugai, ED-71, ED71, Eldecalcitol, Roche, Taisho, Vitamin D
Name (required)
E-mail (will not be published) (required)
Website
Notify me of follow-up comments via email.
